Chang H.-Y.Wang C.-C.YEN-WEN WUChu P.-H.CHIH-CHENG WUHsu C.-H.Wen M.-S.Voon W.-C.Lin W.-S.Huang J.-L.Chen S.-M.Yang N.-I.Chang H.-C.Chang K.-C.Sung S.-H.Shyu K.-G.JIUNN-LEE LINMar G.-Y.Chan K.-C.Kuo J.-Y.Wang J.-H.Chen Z.-C.Tseng W.-K.Cherng W.-J.Yin W.-H.2021-03-182021-03-1820171011-6842https://scholars.lib.ntu.edu.tw/handle/123456789/553699Background: Heart failure (HF) is a global health problem. The Taiwan Society of Cardiology-Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry was a multicenter, observational survey of patients admitted with HFrEF in Taiwan. The aim of this study was to report the one-year outcome in this large-cohort of hospitalized patients presenting with acute decompensated HFrEF. Methods: Patients hospitalized for acute HFrEF were recruited in 21 hospitals in Taiwan. A total of 1509 patients were enrolled into the registry by the end of October 2014. Clinical status, readmission rates and dispensed medications were collected and analyzed 1 year after patient index hospitalization. Results: Our study indicated that re-hospitalization rates after HFrEF were 31.9% and 38.5% at 6 and 12 months after index hospitalization, respectively. Of these patients, 9.7% of themwere readmittedmore than once. At 6 and 12 months after hospital discharge, all-cause mortality rates were 9.5% and 15.9%, respectively, and cardiovascular mortality rateswere 6.8% and 10.5%, respectively. Twenty-three patients (1.5%) underwent heart transplantation. During a follow-up period of 1 year, 46.4% of patients were free from mortality, HF re-hospitalization, left ventricular assist device use and heart transplantation. At the conclusion of follow-up, 57.5% of patients were prescribed either with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; also, 66.3% were prescribed with beta-blockers and 40.8% were prescribed with mineralocorticoid receptor antagonists. Conclusions: The TSOC-HFrEF registry showed evidence of suboptimal practice of guideline-directed medical therapy and high HF re-hospitalization rate in Taiwan. The one-year mortality rate of the TSOC-HFrEF registry remained high. Ultimately, our data indicated a need for further improvement in HF care. ? 2017, Republic of China Society of Cardiology. All rights reserved.[SDGs]SDG3antiarrhythmic agent; anticoagulant agent; antithrombocytic agent; bisoprolol; candesartan; captopril; carvedilol; digitalis; diuretic agent; enalapril; eplerenone; hemoglobin; hydralazine; losartan; metoprolol; nitrate; potassium; ramipril; sodium; spironolactone; troponin I; valsartan; adult; anemia; Article; blood pressure; cardiac resynchronization therapy device; cardiovascular mortality; chronic kidney failure; congestive cardiomyopathy; coronary artery bypass surgery; death; electrocardiography; estimated glomerular filtration rate; female; heart failure with reduced ejection fraction; heart transplantation; heart valve surgery; hospital discharge; hospitalization; human; hyperkalemia; hyponatremia; implantable cardioverter defibrillator; ischemic cardiomyopathy; length of stay; major clinical study; male; middle aged; mortality rate; observational study; outcome assessment; pacemaker implantation; prospective study; sinus rhythm; systolic heart failure; valvular heart diseasejournal article10.6515/ACS20170202A2-s2.0-85015677088